The Council’s first year delivers tangible solutions to strengthen pharmacy talent pipeline and transform the future of pharmacy.
DEERFIELD, Ill. / Feb 04, 2025 / Business Wire / Today marks a milestone for Walgreens as it looks back on the progress made over the last year since the launch of the Walgreens Deans Advisory Council, formed with the goal of enhancing the pharmacy profession and advancing solutions to attract, recruit and create a dynamic workplace for current and future pharmacists.
A year in, the partnership with 17 pharmacy school deans has proven to be effective. With the deans’ work deeply rooted in nurturing the talent pipeline, coupled with Walgreens’ extensive reach and trusted relationships, the collaboration has helped influence and deliver visible progress including:
“Pharmacists continue to serve as the first point of contact for patients entering the health care system,” said John Colaizzi Jr., PharmD, head of enterprise pharmacy practice at Walgreens and co-chair of the Council. “Our work is rooted in the fundamental belief that local, accessible care is in high demand now more than ever. This partnership with the deans builds on our long-standing relationship with schools of pharmacy and is driving meaningful change across the industry to evolve our practice, encourage community pharmacy as a practice setting of choice, and create work environments that are conducive to the well-being of pharmacists everywhere.”
In addition to addressing talent pipeline and financial challenges for pharmacy students, the Council is engaged in ongoing work to ensure the profession’s sustainability through reimbursement reform.
“The deans have been an important voice in our ongoing dialogues with legislators, championing initiatives to stabilize and clarify reimbursement structures, emphasizing fair pricing and recognizing pharmacists’ important role in the healthcare ecosystem,” said Rick Gates, chief pharmacy officer at Walgreens.
Deans are central to fostering the talent pipeline, and Walgreens' technologies, like micro-fulfillment centers and centralized services, are influencing curriculums.
“Having a seat at the table has allowed us to share the latest pharmacy innovations and patient care approaches, ensuring students have hands-on experiences that focus on improving patient healthcare,” said Angela Kashuba, co-chair of the Walgreens Dean Advisory Council and dean of the University of North Carolina Eshelman School of Pharmacy. “The commitment from Walgreens leadership, from CEO Tim Wentworth to Rick Gates, has been key to our success.”
The Walgreens Deans Advisory Council is a long-term commitment to drive systemic change that benefits all pharmacists and the patients they serve. To learn more about the Walgreens Deans Advisory Council, visit walgreensbootsalliance.com/walgreens-pharmacy-deans-advisory-council.
About Walgreens
Walgreens (www.walgreens.com) is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of “more joyful lives through better health,” Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company’s pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation’s most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement.
Last Trade: | US$10.89 |
Daily Change: | 0.09 0.83 |
Daily Volume: | 7,508,331 |
Market Cap: | US$9.410B |
March 06, 2025 January 10, 2025 December 13, 2024 October 15, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load